Rare diseases
Investigational molecules
Locations
Study of nivolumab plus drug combination versus standard first-line therapy in patients with advanced Hodgkin lymphoma
PolandStudy of pelabresib (DAK539) plus ruxolitinib versus placebo plus ruxolitinib in adult patients with myelofibrosis who are JAK‑inhibitor‑naive
PolandLong‑Term Safety and Tolerability of Oral Fesoterodine in Adults with Hallucinations and Delusions Due to Alzheimer’s Disease Psychosis
PolandCemsidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma
PolandRemibrutinib in Chronic Spontaneous Urticaria for Patients Who Benefited from a Previous Remibrutinib Trial
PolandAMG 732 in Patients With Thyroid Eye Disease Who Did Not Respond or Relapsed After Previous Treatment
PolandDuchenne Muscular Dystrophy in Patients with Gene Mutations Amenable to Exon 44 Skipping Treated with Delpacibart Zotadirsen
PolandAsciminib in Pediatric Patients With Philadelphia Positive Chronic Myeloid Leukemia in Chronic Phase
PolandStudy of Tirabrutinib, Rituximab, and Temozolomide in Patients with Relapsed/Refractory Primary Central Nervous System Lymphoma
PolandObrixtamig, Carboplatin, and Etoposide for First-Line Treatment of Advanced Extrapulmonary Neuroendocrine Carcinoma in DLL3-Positive Patients
PolandICP-332 for Adults with Prurigo Nodularis
PolandA Study of BI 764532, Atezolizumab, Carboplatin, and Etoposide in Patients With Extensive-Stage Small Cell Lung Cancer
PolandTell us about your condition – we search every trial in Europe and connect you with the right site.
